Lucid Diagnostics (LUCD), a unit of PAVmed (PAVM), said Tuesday it agreed to sell 13.9 million shares at $1.10 each in a registered direct offering.
Gross proceeds are anticipated to total $15.3 million and the transaction is expected to close on Wednesday, the company said.
Lucid Diagnostics said net proceeds will be used for working capital and general corporate purposes.
The company's shares were down nearly 18% in recent Tuesday premarket activity.